Giuliana Grossi

New prognostic model enhances methotrexate monitoring for immune-mediated inflammatory diseases.

Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose discuss the latest data on the breakthrough biologic for severe asthma.

Patients treated with NAL ER demonstrated a 75.1% decrease in daytime cough frequency and a 76.1% decrease in 24-hour cough frequency compared with placebo.

Investigators Dr. Jean-Pierre Llanos Ackert and Dr. Chris Ambrose share insight on the efficacy of tezepelumab in severe, uncontrolled asthma, and baseline predictors of enhanced response which support tezepelumab as a promising biologic treatment option.

Celularity's clinical trial of CYNK-001 for relapsed and refractory AML showed excellent tolerability, significant graft-versus-leukemia effects, and potential for flexible therapeutic development.

Late-breaking data validates the FDA clearance of Cytovale's IntelliSep test, demonstrating its potential to aid in the early detection of sepsis in US emergency departments, with the aim of improving patient outcomes.

Late-breaking data from ATS 2023 show new positive evidence of the innovative in-vitro diagnostic tool IntelliSep test that measures the viscoelastic properties of leukocytes, showing promising results for rapid sepsis diagnosis in EDs.

Data indicates that addressing mood disorders in patients not only improves mood symptoms but also demonstrates positive effects on certain cardiac events, suggesting benefits for both mental and physical well-being.

Key opinion leaders at ATS 2023 urge physicians to treat more than just symptoms in patients with COPD and consider mood disorders and cardiac comorbidities.

At ATS 2023, Dr. Galiatsatos illuminates what makes lung cancer screening different and how the screening approach is changing.

In an interview at ATS 2023, Dr. Rutland stresses the importance of studying the immune system's response to various diseases, emphasizing the potential impact of pipeline molecules.

Dr. Panagis Galiatsatos explains the new lung cancer screening aims to address the disparities of disease onset and progression across different racial populations.

Unlike other screenings, lung cancer screening is new and patients need to know what happens next, according to Dr. Panagis Galiatsatos.

Dr. Rutland emphasizes the importance of understanding cellular communication and its potential to manipulate disease processes for patient benefit, including the observed link between ILD, inflammation, scarring, and pulmonary hypertension.

Promising results from the ATS Conference suggest that AD109, an oral treatment for obstructive sleep apnea, demonstrated significant reduction of AHI and potential mitigation of daytime fatigue.

Dupilumab demonstrates significant improvements in patients with COPD, type 2 inflammation by reducing exacerbations, improving lung function and quality of life, and alleviating respiratory symptoms.

AD109 shows the potential to address an unmet need in obstructive sleep apnea treatment.

The study revealed that healthcare workers with psychiatric disorders had slightly lower Anti-SARS-CoV-2-Spike IgG levels before their third COVID-19 vaccination, but this effect was mediated by age and body mass index.

As a result of these practices, asthma disparities have been amplified due to the concentration of poverty, heightened exposure to environmental hazards, and inadequate housing quality in these communities.

Children with autism experience higher frequencies of restless sleep, circadian rhythm disorder, and insomnia, indicating the need for targeted sleep evaluation.

The increased use of tobacco-free nicotine products highlights the need for physicians to stay informed about nicotine pouches and be prepared for discussions with their patients.

Relocation led to a reduction in asthma exacerbations, exceeding the effect of inhaled corticosteroids, and was similar to biologic agents.

The phase 3 clinical trials evaluating ziritaxestat for treating idiopathic pulmonary fibrosis showed no improvement in clinical outcomes leading to the termination of the trials due to lack of efficacy.

At West Penn Hospital, the harmonica program, currently in the pilot phase, aims to demonstrate its benefits in improving respiratory symptoms, reducing exacerbations, and enhancing patients' quality of life.

Rituximab biosimilars, Rixathon and Truxima, demonstrate promise in the treatment of immune thrombocytopenia, with comparable efficacy and safety profiles to the reference product.

There have been long stretches of time between the innovation of epinephrine delivery in the allergy space.

"Playing the harmonica has a therapeutic effect because of the pursed lip breathing technique it requires," Dr. Becky Jordan says in an interview.

The findings suggest rural patients treated for gout had higher treatment adherence compared with urban patients.

Results from the NIH RECOVER Initiative study show an 89% risk of long COVID in women with sleep apnea and 59% in men when compared with adults without the condition.

Bryn Pharma is planning to submit the New Drug Application for Utuly this year and expects to receive approval early next year.